These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28870953)

  • 21. Manual contouring based volumetric evaluation for colorectal cancer with liver limited metastases: a comparison with RECIST.
    Fang WJ; Lam KO; Ng SC; Choi CW; Kwong DL; Zheng SS; Lee VH
    Asian Pac J Cancer Prev; 2013; 14(7):4151-5. PubMed ID: 23991968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
    Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
    AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Yoshita H; Hosokawa A; Ueda A; Ando T; Kajiura S; Kato H; Kawabe H; Tomizawa G; Horikawa N; Yabuhita K; Note M; Sugiyama T
    Digestion; 2014; 89(1):43-8. PubMed ID: 24458112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma.
    Usakova V; Sevcikova K; Usak J; Bartosova Z; Mikulova M; Spanik S
    Neoplasma; 2013; 60(1):83-91. PubMed ID: 23067221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
    Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.
    Pietrantonio F; Orlandi A; Inno A; Da Prat V; Spada D; Iaculli A; Di Bartolomeo M; Morosi C; de Braud F
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):272-81. PubMed ID: 25958297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer.
    Cheng K; Chen Y; Li LH; Liu JY
    J Cancer Res Ther; 2013; 9(4):727-9. PubMed ID: 24518728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Akinwande O; Scoggins C; Martin RC
    Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
    Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
    Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
    Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
    J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
    Narayanan G; Barbery K; Suthar R; Guerrero G; Arora G
    Anticancer Res; 2013 May; 33(5):2077-83. PubMed ID: 23645758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [What is the contribution of tumor response in colorectal cancer?].
    Bachet JB; Paoletti X; Fournier L; Rougier P
    Bull Cancer; 2013; 100(7-8):743-55. PubMed ID: 23831844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.
    Cercek A; Boucher TM; Gluskin JS; Aguiló A; Chou JF; Connell LC; Capanu M; Reidy-Lagunes D; D'Angelica M; Kemeny NE
    J Surg Oncol; 2016 Nov; 114(6):655-663. PubMed ID: 27566258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. We should desist using RECIST, at least in GIST.
    Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
    J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.